EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?

Toshiaki Iba, Jerrold H Levy, Cheryl L Maier, Jean M Connors, Marcel Levi

Journal of Thrombosis and Haemostasis · 2024

DOI: 10.1016/j.jtha.2024.02.013 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Thrombosis and Haemostasis, 2024. Verfasst von Toshiaki Iba und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan. Electronic address: toshiiba@juntendo.a…. Hauptthemen laut MEDLINE: COVID-19, Blood Coagulation Disorders, SARS-CoV-2. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Coagulopathy alongside micro- and macrovascular thrombotic events were frequent characteristics of patients presenting with acute COVID-19 during the initial stages of the pandemic. However, over the past 4 years, the incidence and manifestations of COVID-19-associated coagulopathy have changed due to immunity from natural infection and vaccination and the appearance of new SARS-CoV-2 variants. Diagnostic criteria and management strategies based on early experience and studies for COVID-19-associated coagulopathy thus require reevaluation. As many other infectious disease states are also associated with hemostatic dysfunction, the coagulopathy associated with COVID-19 may be compounded, especially throughout the winter months, in patients with diverse etiologies of COVID-19 and other infections. This commentary examines what we have learned about COVID-19-associated coagulopathy throughout the pandemic and how we might best prepare to mitigate the hemostatic consequences of emerging infection agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19Blood Coagulation DisordersSARS-CoV-2HumansBlood CoagulationRisk FactorsHemostasisAnticoagulantsAcute Disease

Stichwörter der Autor:innen

COVID-19anticoagulationcoagulopathycritical illnesshyperviscosityimmunitythromboembolismthrombosis

Substanzen

Anticoagulants

Autor:innen und Institutionen

  • Department of Emergency and Disaster Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan. Electronic address: toshiiba@juntendo.ac.jp.
  • Department of Anesthesiology, Critical Care, and Surgery, Duke University School of Medicine, Durham, North Carolina, USA.
  • Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
  • Hematology Division Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
  • Department of Vascular Medicine, Amsterdam University Medical Center, Amsterdam, The Netherlands; Department of Medicine, University College London Hospitals NHS Foundation Trust, Cardio-metabolic Programme-National Ins…

Zitieren

APA

Iba, T., Levy, J. H., Maier, C. L., Connors, J. M., & Levi, M. (2024). Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?. Journal of Thrombosis and Haemostasis. https://doi.org/10.1016/j.jtha.2024.02.013

Vancouver

Iba T, Levy JH, Maier CL, Connors JM, Levi M. Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?. Journal of Thrombosis and Haemostasis. 2024. doi:10.1016/j.jtha.2024.02.013

BibTeX
@article{Iba2024,
  author = {Iba, Toshiaki and Levy, Jerrold H and Maier, Cheryl L and Connors, Jean M and Levi, Marcel},
  title = {Four years into the pandemic, managing COVID-19 patients with acute coagulopathy: what have we learned?},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2024},
  doi = {10.1016/j.jtha.2024.02.013}
}
Kostenlos starten →